x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012857
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro85 of human SQLE protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SQLE |
| UniProt No. | Q14534 |
| Gene ID | 6713 |
| Gene Description | Squalene monooxygenase, also known as squalene epoxidase, catalyzes the stereospecific oxidation of squalene to -2, 3-epoxysqualene and is considered to be a critical rate-limiting enzyme in cholesterol biosynthesis downstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. The N-terminal region of SQLE is anchored to the endoplasmic reticulum membrane via a re-entrant loop, and undergoes a conformational change in response to elevated cholesterol levels. This cholesterol-mediated conformational change promotes the interaction of SQLE with the E3 ligase MARCH6, leading to targeted ubiquitination and proteasomal degradation. Altered expression of SQLE is associated with perturbed cholesterol homeostasis and tumor progression, prompting investigation of the therapeutic potential of SQLE. Moreover, research studies have shown that cholesterol auxotrophy and subsequent squalene accumulation observed in certain cancers may prevent oxidative cell death and represent a targetable vulnerability to SQLE inhibitors. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
